男性乳腺癌36例分子分型和临床特征分析

  目的　研究男性乳腺癌（MBC）的发病因素、分子分型、手术方式等并对其预后进行评估。方法　回顾性分析近5年住院的MBC患者36例，选取同期女性乳腺癌（WBC）患者100例作为对照组，病理类型以浸润性导管癌为主；根据雌激素受体（ER）、孕激素受体（PR）和人类表皮生长因子受体2（Her-2）的表达情况将MBC分为4种分子亚型，即Luminal A型、Luminal B型、Her-2型和Basal-like型。结果　Luminal A组较Luminal B组乳腺癌患者组织学Ⅲ级的比例低，差异有统计学意义（χ2＝1.197，P＜0.05）。结论　MBC发病率低，预后较差，病理类型以浸润性导管癌为主。MBC患者多见Luminal A型和Luminal B型，Luminal A型较Luminal B型乳腺癌患者组织学Ⅲ级的比例低。

Analysis of molecular classification and clinical characteristics in 36 patients with male breast cancer

Objective　 To analyze molecular classification and male breast cancer (MBC) triggers, clinical characteristics in patients with MBC and evaluate the prognosis. Methods　36 MBC patients enrolled in the past 5 years were retrospectively analyzed. 100 patients with women breast cancer (WBC) in the same period were randomly selected as control group. The primary pathological type of MBC was the infiltrating ductal carcinoma. According to the expressions of estrogen receptor (ER), progesterone receptor (PR), and the epidermal growth factor receptor 2 (Her-2), the MBC can be divided into 4 kinds of molecular subtypes, Luminal type A, Luminal type B, Her-2 type, and Basal-like type. Results　The ratio of MBC patients with grade Ⅲ was lower in the Luminal group A than that in the Luminal group B. There were significant differences (χ 2 =1.197, P < 0.05) between these two groups. Conclusion　The incidence rate of MBC is low but the prognosis is poor. The primary pathological type is the infiltrating ductal carcinoma. The ratio of MBC patients with grade Ⅲ is lower in the common Luminal group A than that in the common Luminal group B.